Biotech Stock Review Adds One Medical (ONEM) $28.50 to Watchlist.
It Ain't Cheap at $3.5 Billion.It's Near Doubled Since March 20th.But Look at the Growth.Look at the Cash.Don't Look at the Bottom...
Update: Biotech 5 Pack. 5 Biotech Stocks, we Expected to Double in 2020.
No Doubles Yet, But They're Doing Rather Well, Considering Everything. Our Confidence Remains Unwavered. Best Performer up 63%.
Citius Pharma (CTXR) Seeks Expeditious Pathway Into the Clinic, for CoronaVirus Related Acute Respiratory...
Sumbmits pre-IND Into Coronavirus Treatment Acceleration Program (CTAP).
Citius Announces Pre-IND Submission to FDA Under the Coronavirus...
European Hand Sanitizer Market Expected to Reach $9.4 Billion by 2027.
Growing at a CAGR of 38.4% during 2019–2027.
The European hand sanitizer market was valued at US$ 641.7 million...
Antibiotic-Resistant Super Gonorrhea (CDC).
"We are currently down to one last recommended and effective class of antibiotics, cephalosporins, to treat this common...
CDC’s Worst-Case Coronavirus Model: 214 Million Infected, 1.7 Million Dead (Intelligencer)
A recent CDC projection estimated that the U.S. coronavirus epidemic could infect between 160 million and 214 million people over a period...
‘Amazing potential.’ UM doctor to start stem cell trial for coronavirus patients (Miami Herald)
BY BEN CONARCK APRIL 16, 2020
A team of doctors at the University of Miami won emergency federal approval...
FDA Authorizes Athersys (ATHX) to Initiate a Pivotal Clinical Trial!
FDA Authorizes Athersys to Initiate a Pivotal Clinical Trial Evaluating MultiStem® Cell Therapy in Patients With COVID-19 Induced Acute Respiratory Distress Syndrome.
Exosomes, Extracellular Vesicles, and the CoronaVirus.
Uploading a Series of Articles on Extracellular Vesicles, Including Potential Effects on the CoronaVirus and ARDS.
Article #1:...
Adding Corbis Pharma (CRBP) $5.55 to Watch List.
Running Clinical Trials Full Steam With $46 Million Banked in Late February.
Not thinly, but lightly traded. Ready,...
Latest article
Ardelyx (ARDX) Reports First Quarter 2024 Showing $204 Million in Cash!
When we added Ardelyx (ARDX) to the Watch List in November of 2022, the market cap near $80 million. Now it's...
GeoVax to Provide Corporate Update on Tuesday May 14, 2024.
Still our favorite biotech microcap, still our favorite management team, and our favorite risk to reward idea with a $4 million market...
NovaVax (NVAX) Roars Higher, Gaining 225% a $1.2 Billion Increase, at the Blink of...
Sanofi (SNY) Announces Partnership - $500 Million Upfront, plus $700 million in Milestones with NovaVax (NVAX). And some investors say Covid is...
